UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000035533
Receipt number R000040483
Scientific Title Fulvestrant and CDK4/6 inhibitor as first line hormonal therapy for locally advanced/ metastatic disease for Patients with Hormone receptor positive HER2 negative breast cancer -observational study
Date of disclosure of the study information 2019/01/13
Last modified on 2023/01/29 12:50:37

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Fulvestrant and CDK4/6 inhibitor as first line hormonal therapy for locally advanced/ metastatic disease for Patients with Hormone receptor positive HER2 negative breast cancer -observational study

Acronym

SBP-11

Scientific Title

Fulvestrant and CDK4/6 inhibitor as first line hormonal therapy for locally advanced/ metastatic disease for Patients with Hormone receptor positive HER2 negative breast cancer -observational study

Scientific Title:Acronym

SBP-11

Region

Japan


Condition

Condition

breast cancer

Classification by specialty

Breast surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy and the safety of fulvestrant and CDK4/6 inhibitor as first line hormonal therapy for locally advanced/ metastatic disease for Patients with Hormone receptor positive HER2 negative breast cancer.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

PFS

Key secondary outcomes

CBR, OS, ORR, TTF, Safety, compliance


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Female

Key inclusion criteria

Locally advanced/ metastatic disease for Patients with Hormone receptor positive HER2 negative breast cancer pretreated with no hormonal therapy for MBC.

1 Adaptation for Fulvestrant and CDK4/6 inhibitor and the informed consent is obtained.
2 age >=20,female, regardless of menstrual status.
3 locally advanced/ metastatic breast cancer histologically confirmed
4 Hormone receptor positive breast cance confirmed by Immunohistochemically.
5 HER2 negative breast cance confirmed by Immunohistochemically or ISH.
6 ECOG PS: 0-2
7 non-hematological AE( CTCAE v4.0-JCOG) <= grade 2
7 no major organ dysfunction nor bone marrow dysfunction.
8 with or without evaluable lesions (with evaluable lesions preferred)
9 1st line hormonal therapy for MBC ( 1regimen fo chemotherapy is allowed)
10 with documented informed consent.

Key exclusion criteria

1 with life-threatenings
2 symptomatic brain metastasis
3 eligible for inclusion criteria of PALOMA-3
4 pretreated with hormonal therapy for MBC
5 pregnancy or breast feeding or unwilling to contraception
6 long QT syndrome or similar diseases
7 Electrolyte abnormality causing long QT syndrome
8 uncontrolled hypertension, symptomatic heart failure, unstable angina, severe arrhythmia or acute myocardial infarction within 12 months
9 obvious pulmonary fibrosis or interstitial pneumonia
10 active infection
11 other severe comorbidity
12 another active cancer
13 allergic for fulvestrant or CDK4/6 inhibitor
14 other inappropriate patients

Target sample size

75


Research contact person

Name of lead principal investigator

1st name Shinichiro
Middle name
Last name Kubo

Organization

Fukuyama City Hospital

Division name

Department of Breast and thyroid surgery

Zip code

721-08511

Address

5-23-1 Zao-cho, Fukuyama city , Hiroshisma

TEL

084-941-5151

Email

kubokubobo@yahoo.co.jp


Public contact

Name of contact person

1st name Naruto
Middle name
Last name Taira

Organization

Setouchi Breast Project Comprehensive Support Organization

Division name

Clinical trial committee

Zip code

700-8558

Address

2-5-1, Shikata, Kita-ku, Okayama,Japan

TEL

086-235-7265

Homepage URL


Email

info@setouchi-bp.com


Sponsor or person

Institute

Setouchi Breast Project Comprehensive Support Organization

Institute

Department

Personal name



Funding Source

Organization

Setouchi Breast Project Comprehensive Support Organization

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethics Committee, Fukuyama City Hospital

Address

5-23-1 Zao-cho, Fukuyama city , Hiroshisma,Japan

Tel

084-941-5151

Email

shimin-byouin@city.fukuyama.hiroshima.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 01 Month 13 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2018 Year 11 Month 14 Day

Date of IRB

2018 Year 11 Month 29 Day

Anticipated trial start date

2018 Year 12 Month 01 Day

Last follow-up date

2025 Year 06 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

clinical data


Management information

Registered date

2019 Year 01 Month 13 Day

Last modified on

2023 Year 01 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000040483


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name